Published in Lab Business Week, November 12th, 2006
Preclinical trials conducted by the company have shown that CF102 performs well in the inhibition of liver cancer in animal models. In addition, it was proven that the A3 Adenosine receptor, which is the drug target, is over-expressed in liver cancer tumors. The company has recently developed an assay that enables a blood test to determine the receptor level before treatment initiation.
Liver cancer attacks approximately...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.